Fibric acids: Effects on lipids and lipoprotein metabolism

The American Journal of Medicine

Volumn 83, Issue 5 SUPPL. 2, 1987, Pages 9-20

  Grundy, Scott M ^a   Vega, Gloria Lena ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; VERY LOW DENSITY LIPOPROTEIN;

HUMAN; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; SHORT SURVEY;

ANTILIPEMIC AGENTS; BEZAFIBRATE; BILE ACIDS AND SALTS; CHOLESTEROL; CLOFIBRATE; GEMFIBROZIL; HUMAN; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIVER; PENTANOIC ACIDS; PROCETOFEN; TRIGLYCERIDES;

EID: 0023634449     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(87)90866-7     Document Type: Article

References (56)

1. Gallbladder disease as a side effect of drugs influencing lipid metabolism
2. A cooperative trial in the primary prevention of ischemic heart diseases using clofibrate
3. The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of postheparin plasma in male patients with hyperlipoproteinemia
4. Clofibrate increases lipoprotein lipase activity in adipose tissue of hypertriglyceridaemic patients
5. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia
6. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridemic patients with bezafibrate
7. Comparisons of clofibrate and caloric restriction on transport of very low density lipoprotein triglycerides
8. Effects of weight reduction on obesity
9. Accelerated triglyceride secretion: a metabolic consequence of obesity
10. Influence of gemfibrozil on metabolism of cholesterol and plasma triglycerides in man
11. On the mechanism of action Atromid-S on triglyceride transport in man
12. The dynamics of plasma triglyceride turnover: effect of Atromid-S
13. The dynamics of plasma triglyceride turnover in man
14. Mechanism of the hypolipidemic effect of clofibrate in postabsorptive man
15. An overview of the effects of pchlorophenoxyisobutyric acid derivatives on lipoprotein metabolism
16. On the mode of action of lipid lowering agents. V. Kinetics of the inhibition in vitro of rat acetyl CoA carboxylase
17. The hypolipidemic effect of gemfibrozil (CI-719) in laboratory animals
18. Effect of CPIB ester on plasma free fatty acid levels in man
19. Effect of chlorophenoxyisobutyric acid on fat mobilizing lipolysis and cyclic AMP levels in rat epididymal fat
20. The mechanism of clofibrate and tetranicotinylfructose (Bradilan) on the kinetics of plasma free fatty acids and triglyceride transport in type IV and type V hypertriglyceridaemia
21. Mechanism of the hypolipemic effect of clofibrate in glucose-fed men
22. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
23. Lipoprotein receptors in the liver: Control signals for plasma cholesterol traffic
24. Mahley RW, Weisgraber KH, Innerarity TL: Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta 575: 81-91.
25. Lipoprotein receptors and cholesterol homeostasis
26. Catabolism of very low density lipoprotein B apoprotein in man
27. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia
28. Metabolic relationships among the plasma lipoproteins: reciprocal changes in the concentrations of very low and low density lipoproteins in man
29. Effects of hypolipidemia regimes on serum lipoproteins
30. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease
31. Heterogeneity of familial hyperlipoproteinemia type II on the basis of fasting plasma triglyceride/cholesterol ratio and plasma cholesterol response to ethyl p-chlorophenoxyisobutyrate
32. Colestipol and clofibrate in hypercholesterolemia
33. Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia
34. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects
35. Fenofibrate: influence on circulating lipids and side effects in medium and long-term clinical use
36. The metabolism of apolipoprotein B in subjects with hypertriglyceridemia and polydisperse LDL
37. Kinetic heterogeneity of low density lipoprotein in primary hypertriglyceridemia
38. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia
39. Plasma triglyceride determines structure-composition in low and high density lipoproteins
40. Defective metabolism of hypertriglyceridemic lipoprotein in cultured human skin fibroblasts
41. Low density lipoprotein metabolism in hypertriglyceridemic and normolipidemic patients with coronary heart disease
42. Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects
43. Low density lipoprotein metabolism in familial combined hyperlipidemia: mechanism of the multiple lipoprotein phenotype expression
44. High density lipoprotein metabolism
45. Mechanisms of action of gemfibrozil: comparison of studies in the rat to clinical efficacy
46. Mechanism of action of gemfibrozil on lipoprotein metabolism
47. Mode of action of the lipid lowering agents clofibrate and BM 15075 on cholesterol biosynthesis in rat liver
48. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in freshly isolated human mononuclear cells by fenofibrate
49. Mechanism of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia
50. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterolgenesis produced by Penicillium citrinum
51. Competitive inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites having hypocholesterolemic activity
52. An overview of the effects of pchlorophenoxyisobutyric acid derivatives on lipoprotein metabolism
53. Influence of inhibition of 3-hydroxy-3-methylglutaryl CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects of cholesterol balance
54. Colestipol, clofibrate and phytosterols in combined therapy of hyperlipidemia
55. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia
56. Effects of fenofibrate on bile lipid composition